Geographic differences in the contribution of ubiA mutations to high-level ethambutol resistance in Mycobacterium tuberculosis

Antimicrobial Agents and Chemotherapy

Volumn 60, Issue 7, 2016, Pages 4101-4105

  Lingaraju, Subramanya ^a   Rigouts, Leen ^b,c   Gupta, Aditi ^a   Lee, Jongseok ^d   Umubyeyi, Alaine Nyaruhirira ^e   Davidow, Amy L ^f   German, Susan ^f   Cho, EunJin ^d   Lee, Ji Im ^d   Cho, Sang Nae ^d,g   Kim, Cheon Tae ^h   Alland, David ^a   Safi, Hassan ^a  

^a RUTGERS NEW JERSEY MEDICAL SCHOOL   (United States)

^b INSTITUTE OF TROPICAL MEDICINE   (Belgium)

^c UNIVERSITY OF ANTWERP   (Belgium)

^d International Tuberculosis Research Center   (South Korea)

^e Management Sciences for Health   (South Korea)

^f RUTGERS SCHOOL OF PUBLIC HEALTH   (United States)

^g Yonsei University College of Medicine   (South Korea)

^h Masan National Hospital   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

ETHAMBUTOL; MEMBRANE PROTEIN; BACTERIAL PROTEIN; TUBERCULOSTATIC AGENT;

AFRICA; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL GENE; BACTERIAL MUTATION; BACTERIAL STRAIN; CLINICAL LABORATORY; CONTROLLED STUDY; EMBB GENE; GENE AMPLIFICATION; GENOTYPE; GEOGRAPHIC ORIGIN; MINIMUM INHIBITORY CONCENTRATION; MUTATION RATE; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; NUCLEOTIDE SEQUENCE; POLYMERASE CHAIN REACTION; PREVALENCE; PRIORITY JOURNAL; PROTEIN DOMAIN; RWANDA; SOUTH KOREA; UBIA GENE; DRUG EFFECTS; GENETICS; MICROBIAL SENSITIVITY TEST; MUTATION;

ANTITUBERCULAR AGENTS; BACTERIAL PROTEINS; DRUG RESISTANCE, BACTERIAL; ETHAMBUTOL; MICROBIAL SENSITIVITY TESTS; MUTATION; MYCOBACTERIUM TUBERCULOSIS;

EID: 84977567408     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.03002-15     Document Type: Article

References (27)

1. American Thoracic Society, CDC, and Infectious Diseases Society of America. 2003. Treatment of tuberculosis. MMWR Recommend Rep 52(RR-11):1-77.
2. Telenti A, Philipp WJ, Sreevatsan S, Bernasconi C, Stockbauer KE, Wieles B, Musser JM, Jacobs WR. 1997. The emb operon, a gene cluster of Mycobacterium tuberculosis involved in resistance to ethambutol. Nat Med 3:567-570. http://dx.doi.org/10.1038/nm0597-567.
3. Ramaswamy SV, Amin AG, Goksel S, Stager CE, Dou S-J, El Sahly H, Moghazeh SL, Kreiswirth BN, Musser JM. 2000. Molecular genetic analysis of nucleotide polymorphisms associated with ethambutol resistance in human isolates of Mycobacterium tuberculosis. Antimicrob Agents Chemother 44:326-336. http://dx.doi.org/10.1128/AAC.44.2.326-336.2000.
4. Safi H, Sayers B, Hazbon MH, Alland D. 2008. Transfer of embB codon 306 mutations into clinical Mycobacterium tuberculosis strains alters susceptibility to ethambutol, isoniazid, and rifampin. Antimicrob Agents Chemother 52:2027-2034. http://dx.doi.org/10.1128/AAC.01486-07.
5. Starks AM, Gumusboga A, Plikaytis BB, Shinnick TM, Posey JE. 2009. Mutations at embB codon 306 are an important molecular indicator of ethambutol resistance in Mycobacterium tuberculosis. Antimicrob Agents Chemother 53:1061-1066. http://dx.doi.org/10.1128/AAC.01357-08.
6. Safi H, Fleischmann RD, Peterson SN, Jones MB, Jarrahi B, Alland D. 2010. Allelic exchange and mutant selection demonstrate that common clinical embCAB gene mutations only modestly increase resistance to ethambutol in Mycobacterium tuberculosis. Antimicrob Agents Chemother 54:103-108. http://dx.doi.org/10.1128/AAC.01288-09.
7. Plinke C, Cox HS, Zarkua N, Karimovich HA, Braker K, Diel R, Rüsch-Gerdes S, Feuerriegel S, Niemann S. 2010. embCAB sequence variation among ethambutol-resistant Mycobacterium tuberculosis isolates without embB306 mutation. J Antimicrob Chemother 65:1359-1367. http://dx.doi.org/10.1093/jac/dkq120.
8. Cui Z, Li Y, Cheng S, Yang H, Lu J, Hu Z, Ge B. 2014. Mutations in the embC-embA intergenic region contribute to Mycobacterium tuberculosis resistance to ethambutol. Antimicrob Agents Chemother 58:6837-6843. http://dx.doi.org/10.1128/AAC.03285-14.
9. Safi H, Lingaraju S, Amin A, Kim S, Jones M, Holmes M, McNeil M, Peterson SN, Chatterjee D, Fleischmann R, Alland D. 2013. Evolution of high-level ethambutol-resistant tuberculosis through interacting mutations in decaprenylphosphoryl-[beta]-D-arabinose biosynthetic and utilization pathway genes. Nat Genet 45:1190-1197. http://dx.doi.org/10.1038/ng.2743.
10. He L, Wang X, Cui P, Jin J, Chen J, Zhang W, Zhang Y. 2015. ubiA (Rv3806c) encoding DPPR synthase involved in cell wall synthesis is associated with ethambutol resistance in Mycobacterium tuberculosis. Tuberculosis 95:149-154. http://dx.doi.org/10.1016/j.tube.2014.12.002.
11. Xu Y, Jia H, Huang H, Sun Z, Zhang Z. 2015. Mutations found in embCAB, embR, and ubiA genes of ethambutol-sensitive and -resistant Mycobacterium tuberculosis clinical isolates from China. Biomed Res Int 2015:951706. http://dx.doi.org/10.1155/2015/951706.
12. Vincent V, Rigouts L, Nduwamahoro E, Holmes B, Cunningham J, Guillerm M, Nathanson CM, Moussy F, De Jong B, Portaels F, Ramsay A. 2012. The TDR Tuberculosis Strain Bank: a resource for basic science, tool development and diagnostic services. Int J Tuberc Lung Dis 16:24-31. http://dx.doi.org/10.5588/ijtld.11.0223.
13. Umubyeyi AN, Vandebriel G, Gasana M, Basinga P, Zawadi JP, Gatabazi J, Pauwels P, Nzabintwali F, Nyiramasarabwe L, Fissette K, Rigouts L, Struelens MJ, Portaels F. 2007. Results of a national survey on drug resistance among pulmonary tuberculosis patients in Rwanda. Int J Tuberc Lung Dis 11:189-194.
14. Chakravorty S, Lee JS, Cho EJ, Roh SS, Smith LE, Lee J, Kim CT, Via LE, Cho S-N, Barry CE, Alland D. 2015. Genotypic susceptibility testing of Mycobacterium tuberculosis isolates for amikacin and kanamycin resistance by use of a rapid sloppy molecular beacon-based assay identifies more cases of low-level drug resistance than phenotypic Lowenstein-Jensen testing. J Clin Microbiol 53:43-51. http://dx.doi.org/10.1128/JCM.02059-14.
15. van Embden JD, Cave MD, Crawford JT, Dale JW, Eisenach KD, Gicquel B, Hermans P, Martin C, McAdam R, Shinnick TM. 1993. Strain identification of Mycobacterium tuberculosis by DNA fingerprinting: recommendations for a standardized methodology. J Clin Microbiol 31:406-409.
16. Safi H, Barnes PF, Lakey DL, Shams H, Samten B, Vankayalapati R, Howard ST. 2004. IS6110 functions as a mobile, monocyte-activated promoter in Mycobacterium tuberculosis. Mol Microbiol 52:999-1012. http://dx.doi.org/10.1111/j.1365-2958.2004.04037.x.
17. NCCLS. 2003. Susceptibility testing of Mycobacteria, Nocardiae, and other aerobic Actinomycetes; approved standard. NCCLS, Wayne, PA.
18. Galagan JE. 2014. Genomic insights into tuberculosis. Nat Rev Genet 15:307-320. http://dx.doi.org/10.1038/nrg3664.
19. Huang H, Berg S, Spencer JS, Vereecke D, D'Haeze W, Holsters M, McNeil MR. 2008. Identification of amino acids and domains required for catalytic activity of DPPR synthase, a cell wall biosynthetic enzyme of Mycobacterium tuberculosis. Microbiology 154:736-743. http://dx.doi.org/10.1099/mic.0.2007/013532-0.
20. Köser CU, Feuerriegel S, Summers DK, Archer JAC, Niemann S. 2012. Importance of the genetic diversity within the Mycobacterium tuberculosis complex for the development of novel antibiotics and diagnostic tests of drug resistance. Antimicrob Agents Chemother 56:6080-6087. http://dx.doi.org/10.1128/AAC.01641-12.
21. Gutacker MM, Mathema B, Soini H, Shashkina E, Kreiswirth BN, Graviss EA, Musser JM. 2006. Single-nucleotide polymorphism-based population genetic analysis of Mycobacterium tuberculosis strains from 4 geographic sites. J Infect Dis 193:121-128. http://dx.doi.org/10.1086/498574.
22. Shamputa IC, Lee J, Allix-Béguec C, Cho E-J, Lee J-I, Rajan V, Lee EG, Min JH, Carroll MW, Goldfeder LC, Kim JH, Kang HS, Hwang S, Eum S-Y, Park SK, Lee H, Supply P, Cho S-N, Via LE, Barry CE. 2010. Genetic diversity of Mycobacterium tuberculosis isolates from a tertiary care tuberculosis hospital in South Korea. J Clin Microbiol 48:387-394. http://dx.doi.org/10.1128/JCM.02167-09.
23. Filliol I, Motiwala AS, Cavatore M, Qi W, Hazbón MH, Bobadilla del Valle M, Fyfe J, García-García L, Rastogi N, Sola C, Zozio T, Guerrero MI, León CI, Crabtree J, Angiuoli S, Eisenach KD, Durmaz R, Joloba ML, Rendón A, Sifuentes-Osornio J, Ponce de León A, Cave MD, Fleischmann R, Whittam TS, Alland D. 2006. Global phylogeny of Mycobacterium tuberculosis based on single nucleotide polymorphism (SNP) analysis: insights into tuberculosis evolution, phylogenetic accuracy of other DNA fingerprinting systems, and recommendations for a minimal standard SNP set. J Bacteriol 188:759-772. http://dx.doi.org/10.1128/JB.188.2.759-772.2006.
24. Gagneux S, DeRiemer K, Van T, Kato-Maeda M, de Jong BC, Narayanan S, Nicol M, Niemann S, Kremer K, Gutierrez MC, Hilty M, Hopewell PC, Small PM. 2006. Variable host-pathogen compatibility in Mycobacterium tuberculosis. Proc Natl Acad Sci U S A 103:2869-2873. http://dx.doi.org/10.1073/pnas.0511240103.
25. Gagneux S, Small PM. 2007. Global phylogeography of Mycobacterium tuberculosis and implications for tuberculosis product development. Lancet Infect Dis 7:328-337. http://dx.doi.org/10.1016/S1473-3099(07)70108-1.
26. Gafirita J, Umubyeyi A, Asiimwe B. 2012. A first insight into the genotypic diversity of Mycobacterium tuberculosis from Rwanda. BMC Clin Pathol 12:20. http://dx.doi.org/10.1186/1472-6890-12-20.
27. WHO. 2008. Guidelines for the programmatic management of drug-resistant tuberculosis. Emergency update. WHO, Geneva, Switzerland.